Randolph Rough, MD
Cardiovascular Disease · West Des Moines, IANPI 1376525196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by United Therapeutics Corporation at 32.0% of the total. Reporting peaked in 2023 at $1,103 and has fallen 72.6% since, to $302 in 2025.
Across 55 payments — averaging $56.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$987
- Actelion Pharmaceuticals US, Inc.$562
- E.r. Squibb & Sons, L.L.C.$510
- Heartflow, Inc.$242
- Impulse Dynamics (USA) Inc.$188
- Novartis$158
- plus $436 from 11 others
Across 12 payments — averaging $483.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$6K
What the payments were for
- Food & beverage$3,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 10 | $987 |
| Actelion Pharmaceuticals US, Inc. | 8 | $562 |
| E.r. Squibb & Sons, L.L.C. | 6 | $510 |
| Heartflow, Inc. | 7 | $242 |
| Impulse Dynamics (USA) Inc. | 1 | $188 |
| Novartis | 6 | $158 |
| Boehringer Ingelheim | 1 | $124 |
| Philips North America LLC | 1 | $71 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $60 |
| Boston Scientific | 3 | $59 |
| Johnson & Johnson | 4 | $43 |
| Medtronic | 1 | $17 |
| Abbott | 1 | $14 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| Novo Nordisk | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,083 in reported general payments places this provider in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 90 | $2,062,195 |
| OpsumitMacitentan | 145 | $1,892,002 |
| UptraviSelexipag | 73 | $1,774,572 |
| AdempasRiociguat | 61 | $810,597 |
| EliquisApixaban | 599 | $505,406 |
| XareltoRivaroxaban | 203 | $195,619 |
| Orenitram ErTreprostinil Diolamine | 38 | $193,021 |
| Ambrisentan | 49 | $151,229 |
| CamzyosMavacamten | 11 | $89,295 |
| EntrestoSacubitril/Valsartan | 47 | $48,642 |
| Repatha SureclickEvolocumab | 40 | $30,805 |
| JardianceEmpagliflozin | 31 | $20,106 |
| Sildenafil Citrate | 119 | $16,918 |
| Praluent PenAlirocumab | 28 | $15,195 |
| Metoprolol Succinate | 1,059 | $11,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $562 | $3,666,575218 claims |
| Johnson & JohnsonXarelto | $43 | $195,619203 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $510 | $89,29511 claims |
| NovartisEntresto | $158 | $48,64247 claims |
| Boehringer IngelheimJardiance | $124 | $20,10631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in West Des Moines
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Suzanne FeigofskyWest Des Moines$59K
- Robert PaulWest Des Moines$9K
- Lucas GrobenWest Des Moines$6K
- Krishna Theja ReddyWest Des Moines$5K
- Paul WesleyWest Des Moines$2K
- Brian OlshanskyIowa City$219K
- Gursukhman Deep SidhuDavenport$60K
- Tyler RasmussenCedar Rapids$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.